Please provide your email address to receive an email when new articles are posted on . Combined cataract surgery with iStent inject significantly reduced medication burden in patients with glaucoma.

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. A study looked at real-world outcomes with Omni, Hydrus, ...

About iStent inject W Trabecular Micro-Bypass System (U.S.) Indication for Use: The iStent inject W Trabecular Micro-Bypass System Model G2-W is indicated for use in conjunction with cataract surgery ...

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal ...

Effingham (Ill.) Ambulatory Surgery Center began offering the iStent inject Trabecular Micro-Bypass System to improve glaucoma patients’ quality of life, the Effingham Daily News reports. 1. The ...

MENLO PARK, Calif., May 06, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (SGHT) (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative technology that ...

ALISO VIEJO, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal ...

San Clemente-based Glaukos Corp. anticipates strong revenue growth next year for its iStent products, based on a guarantee of reimbursement on procedures that use its iStent implant. Glaukos expects ...

ALISO VIEJO, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal ...

Glaukos secured a new FDA clearance for its miniaturized stent system designed for glaucoma to help drain the inner eye of built-up fluids and normalize intraocular pressure. The company had received ...

Needham expects Glaukos Corp (NYSE:GKOS) to surpass expectations and raise outlook in Q2 FY23, fueled by rebounding iStent inject volumes post-2022 reimbursement-driven declines. An additional upside ...

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today ...